EIC Pre-Accelerator
PRECISION-ECS: predicting cannabinoid response in melanoma
Funded by the European Innovation Council, July 2026 to June 2028.
Read more →Programs and clinical studies
Our programs apply the EndoVia platform to defined research questions with academic, clinical and industry partners. Each one builds evidence for response prediction in a new setting.
Our programs
Read more →Clinical studies
Our models start from patient tissue. Together with clinical partners, we run non-interventional studies that collect residual tumor tissue from standard surgery, with informed consent and ethics approval.
Ongoing
MEL-ECS-P01: Melanoma
Establishing primary cell models (2D cultures and 3D organoids) from cutaneous melanoma tissue to study the endocannabinoid system in cancer. A prospective, non-interventional study with the Institute of Oncology Ljubljana, approved by the Slovenian National Medical Ethics Committee.
In preparation
BC-ECS-P01: Breast cancer
Establishing and characterizing patient-derived breast cancer models, molecularly and functionally, to study the endocannabinoid system and develop personalized therapeutic approaches. A multicenter, prospective, non-interventional study with the Institute of Oncology Ljubljana and University Medical Centre Maribor, including a biobank of tissue, models and data for future research.
These are non-interventional studies. Participants do not receive treatment as part of these studies.
Interested in building a program with us?
Tell us about your compound and the decision ahead. A short, non-confidential description is enough to start.
Discuss a project